12-15岁年龄组，没有单独做。5-11岁做了，还没看到结果

5-11 岁

https://clinicaltrials.gov/ct2/show/NCT04816643

，

 

Phase 1 is the open-label dose-finding portion of the study to evaluate safety, tolerability, and immunogenicity of BNT162b2 on a 2-dose (separated by approximately 21 days) schedule in up to 3 age groups (participants ≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age). Dose finding is being initiated in this study in participants ≥5 to <12 years of age based on the acceptable blinded safety assessment of the 30-μg dose in 12- to 15-year-olds in the C4591001 study.

The purpose of Phase 1 is to identify preferred dose level(s) of BNT162b2 from up to 3 different dose levels in each age group.

 

 

12-15岁，与成年组混在一起

https://clinicaltrials.gov/ct2/show/NCT04368728

在决定剂量的一期临试中，没有包括18岁以下的。12-15岁组，从二期开始加入。这就是为啥俺说厂家“偷工”。

• In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: ≥12 years of age [stratified as 12-15, 16-55 or >55 years of age]).